A. Bruce Lyons

10.2k total citations · 4 hit papers
102 papers, 8.2k citations indexed

About

A. Bruce Lyons is a scholar working on Immunology, Molecular Biology and Microbiology. According to data from OpenAlex, A. Bruce Lyons has authored 102 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Immunology, 31 papers in Molecular Biology and 30 papers in Microbiology. Recurrent topics in A. Bruce Lyons's work include Microbial infections and disease research (27 papers), Veterinary Oncology Research (27 papers) and Immunotherapy and Immune Responses (14 papers). A. Bruce Lyons is often cited by papers focused on Microbial infections and disease research (27 papers), Veterinary Oncology Research (27 papers) and Immunotherapy and Immune Responses (14 papers). A. Bruce Lyons collaborates with scholars based in Australia, United Kingdom and United States. A. Bruce Lyons's co-authors include Christopher R. Parish, Philip D. Hodgkin, Heinrich Körner, Jocelyn M. Darby, Wei Wei, Shanshan Hu, Andrew Docherty, John J. Reynolds, Gillian Murphy and Bryan John Smith and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

A. Bruce Lyons

101 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Determination of lymphocyte division by flow cytometry

1994 1.5k citations A. Bruce Lyons, Christopher R. Parish profile →
Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major

2018 862 citations Jocelyn M. Darby, A. Bruce Lyons et al. Frontiers in Immunology profile →
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity

1985 613 citations A. Bruce Lyons et al. profile →
Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution

2000 561 citations A. Bruce Lyons profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Bruce Lyons Australia	38	3.5k	2.3k	1.5k	981	929	102	8.2k
Sergio Roman‐Roman France	45	2.2k 0.6×	4.5k 1.9×	3.1k 2.0×	1.2k 1.2×	315 0.3×	129	8.9k
Matthew J. Sweet Australia	58	6.3k 1.8×	6.2k 2.7×	1.2k 0.8×	930 0.9×	421 0.5×	175	12.9k
Hans G. Drexler Germany	43	1.6k 0.5×	4.2k 1.8×	1.5k 1.0×	913 0.9×	2.1k 2.3×	249	7.7k
Walter Knapp Austria	59	6.0k 1.7×	2.9k 1.2×	1.6k 1.0×	593 0.6×	1.9k 2.1×	220	10.6k
Robert Hromas United States	55	2.7k 0.8×	6.1k 2.6×	2.7k 1.8×	969 1.0×	1.6k 1.8×	207	10.4k
Andrew Davies United Kingdom	54	3.0k 0.9×	2.2k 1.0×	2.8k 1.9×	906 0.9×	563 0.6×	310	10.7k
William A. Robinson United States	51	2.6k 0.8×	3.6k 1.5×	3.7k 2.4×	1.2k 1.2×	1.7k 1.8×	373	10.6k
Tang‐Yuan Chu Taiwan	40	1.1k 0.3×	2.6k 1.1×	888 0.6×	840 0.9×	433 0.5×	194	5.9k
Steven C. Clark United States	48	5.5k 1.6×	2.9k 1.2×	2.8k 1.8×	505 0.5×	3.6k 3.8×	102	11.5k
David Lo United States	48	6.1k 1.8×	1.7k 0.7×	1.3k 0.9×	588 0.6×	266 0.3×	136	8.9k

Countries citing papers authored by A. Bruce Lyons

Since Specialization

Citations

This map shows the geographic impact of A. Bruce Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bruce Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bruce Lyons more than expected).

Fields of papers citing papers by A. Bruce Lyons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Bruce Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bruce Lyons. The network helps show where A. Bruce Lyons may publish in the future.

Co-authorship network of co-authors of A. Bruce Lyons

This figure shows the co-authorship network connecting the top 25 collaborators of A. Bruce Lyons. A scholar is included among the top collaborators of A. Bruce Lyons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Bruce Lyons. A. Bruce Lyons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Cheng, Yuanyuan, et al.. (2022). Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours. Open Biology. 12(10). 220208–220208. 5 indexed citations

2.

Darby, Jocelyn M., A. Bruce Lyons, Amanda L. Patchett, et al.. (2022). A human adenovirus encoding IFN-γ can transduce Tasmanian devil facial tumour cells and upregulate MHC-I. Journal of General Virology. 103(11). 5 indexed citations

3.

Wilson, Richard, Ruth J. Pye, Julian Ratcliffe, et al.. (2022). Cathelicidin-3 Associated With Serum Extracellular Vesicles Enables Early Diagnosis of a Transmissible Cancer. Frontiers in Immunology. 13. 858423–858423. 8 indexed citations

4.

Patchett, Amanda L., Jocelyn M. Darby, Jinying Chen, et al.. (2021). NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers. Journal of Cancer Research and Clinical Oncology. 147(7). 1973–1991. 11 indexed citations

5.

Flies, Andrew S., Emily J. Flies, Samantha Fox, et al.. (2020). An oral bait vaccination approach for the Tasmanian devil facial tumor diseases. Expert Review of Vaccines. 19(1). 1–10. 24 indexed citations

6.

Patchett, Amanda L., Andrew S. Flies, A. Bruce Lyons, & GM Woods. (2020). Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii). Cellular and Molecular Life Sciences. 77(13). 2507–2525. 13 indexed citations

7.

Tovar, Cesar, Ruth J. Pye, Alexandre Kreiss, et al.. (2017). Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Scientific Reports. 7(1). 43827–43827. 44 indexed citations

8.

Flies, Andrew S., Nicholas B. Blackburn, A. Bruce Lyons, John D. Hayball, & GM Woods. (2017). Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. Frontiers in Immunology. 8. 513–513. 14 indexed citations

9.

Latham, R, David A. Gell, A. Bruce Lyons, et al.. (2017). An isolate of Haemophilus haemolyticus produces a bacteriocin-like substance that inhibits the growth of nontypeable Haemophilus influenzae. International Journal of Antimicrobial Agents. 49(4). 503–506. 22 indexed citations

10.

Li, Xinying, A. Bruce Lyons, GM Woods, & Heinrich Körner. (2017). The absence of TNF permits myeloid Arginase 1 expression in experimental L. monocytogenes infection. Immunobiology. 222(8-9). 913–917. 8 indexed citations

11.

Patchett, Amanda L., R Latham, Kate H. Brettingham‐Moore, et al.. (2015). Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil. Developmental & Comparative Immunology. 53(1). 123–133. 16 indexed citations

12.

Blake, Stephen J., Timothy P. Hughes, & A. Bruce Lyons. (2012). Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. Experimental Hematology. 40(8). 612–621.e6. 13 indexed citations

13.

Fraser, Cara K., Stephen J. Blake, Kerrilyn R. Diener, et al.. (2008). Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology. 37(2). 256–265. 50 indexed citations

14.

Blake, Stephen J., Timothy P. Hughes, Graham Mayrhofer, & A. Bruce Lyons. (2008). The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clinical Immunology. 127(3). 330–339. 90 indexed citations

15.

Petrovsky, Nikolai, Susanne Heinzel, Yoshikazu Honda‐Okubo, & A. Bruce Lyons. (2007). New-age adjuvants: friend or foe?. eCite Digital Repository (University of Tasmania). 1 indexed citations

16.

Lyons, A. Bruce, et al.. (2006). Modulation of Lymphocyte Migration to the Murine Spleen after Marginal Zone Macrophage Phagocytosis of Blood-Borne Particulate Material. Immunological Investigations. 35(1). 75–92. 2 indexed citations

17.

Dewar, Andrea L., Renae Domaschenz, Kathleen Doherty, Timothy P. Hughes, & A. Bruce Lyons. (2003). Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia. 17(9). 1713–1721. 47 indexed citations

18.

Hasbold, Jhagvaral, A. Bruce Lyons, Marilyn R. Kehry, & Philip D. Hodgkin. (1998). Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4. European Journal of Immunology. 28(3). 1040–1051. 7 indexed citations

19.

Hasbold, Jhagvaral, A. Bruce Lyons, Marilyn R. Kehry, & Philip D. Hodgkin. (1998). Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4. European Journal of Immunology. 28(3). 1040–1051. 181 indexed citations

20.

Lyons, A. Bruce & Christopher R. Parish. (1995). Are murine marginal‐zone macrophages the splenic white pulp analog of high endothelial venules?. European Journal of Immunology. 25(11). 3165–3172. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact